Pfizer Just Made the GLP-1 Shot a Once-a-Month Thing
Pfizer's berobenatide just posted Phase 2b data showing a once-monthly GLP-1 shot can deliver competitive weight loss with remarkably few dropouts. Wall Street thinks it's solid but not spectacular, and the real question is whether convenience can beat raw efficacy in a $50B market.
Imagine only going to the gym once a month and still losing weight. That's roughly the pitch Pfizer is making with berobenatide, a GLP-1 obesity drug designed to work with just one injection every 30 days. Phase 2b data from the VESPER program landed this week, and the numbers tell a story Wall Street isn't quite sure how to feel about.
The Three-Act Data Drop
Pfizer's VESPER program actually includes three studies, each testing berobenatide in a slightly different way. Think of them as chapters in the same book.
VESPER-1 tested weekly dosing in people with obesity but without diabetes. At the top dose (2.4 mg weekly), participants lost 15.9% of their body weight over 32 weeks. That's the raw number, not adjusted for placebo. And the weight was still falling; no plateau in sight.
VESPER-3 is the headline act. This one started patients on weekly shots, then switched them to monthly maintenance injections. After 28 weeks, the best monthly regimen delivered 12.3% placebo-adjusted weight loss. Every single dose group beat placebo with a p-value under 0.001. Again, no plateau. Weight kept dropping.
VESPER-2 looked at patients who had both obesity and type 2 diabetes. Weekly berobenatide cut HbA1c (a key blood sugar marker) by 2.2 percentage points, compared to just 0.2 for placebo. That's a massive gap for a glucose control metric.
Why Monthly Matters More Than You Think
The obesity drug world runs on a simple truth: people stop taking their medicine. Even with weekly shots like Wegovy and Zepbound, real-world data paint a grim picture. Roughly 68% of patients quit their GLP-1 obesity therapy within a year. Only about 30 to 50% stick with weekly injections at the 12-month mark.
Every injection is a decision point, a moment where someone can say "not today." Weekly dosing means 52 of those moments per year. Monthly dosing cuts that to 12. It's the same logic that makes automatic bill pay work better than writing checks: fewer chances to bail.
Get tomorrow's biotech intelligence before your competitors.
Join thousands of biotech professionals who start their day with our free, daily briefing.
There's real evidence behind this thinking. A meta-analysis of injectable GLP-1 drugs found that moving from daily to weekly dosing reduced non-adherence by about 11%. The pattern is consistent across countries and datasets. Less frequent dosing keeps people on their meds.
Monthly is the logical next step. And berobenatide is the first GLP-1 to post robust mid-stage data proving it can actually work at that interval.
The Secret Sauce: Molecular Velcro and Biased Signaling
So how do you make a drug last a full month in the body? Pfizer's engineers used two tricks.
First, they designed the molecule with something called halo-lipidation, a chemical modification that makes berobenatide stick to albumin (a protein that circulates in your blood for weeks). Think of it as molecular Velcro. Instead of getting filtered out by your kidneys in hours, the drug hitches a ride on albumin and stays active for roughly 15 days per half-life. That's long enough to cover a full month.
Second, berobenatide is what scientists call "fully biased" toward cAMP signaling at the GLP-1 receptor. In plain English: it activates the appetite-suppressing pathway without triggering as much of the pathway that causes nausea and receptor shutdown. The result is a drug that works longer and may cause fewer gut problems.
The tolerability data back this up. The injection volume is just 0.5 mL, about one-tenth of a teaspoon. Pfizer reports low rates of the gastrointestinal side effects (nausea, vomiting) that plague other GLP-1 drugs, even with rapid dose escalation.
Pfizer's Rocky Road to This Moment
It's worth remembering how Pfizer got here, because the journey was anything but smooth.
The company originally bet on oral GLP-1 pills. It had three of them: lotiglipron, danuglipron, and PF-06954522. All three are now dead. Lotiglipron was killed in 2023 over liver enzyme concerns. Danuglipron survived longer but suffered from brutal GI side effects (over 50% discontinuation rates in Phase 2b with the twice-daily version). A potential liver injury case in the once-daily reformulation, combined with regulatory feedback, sealed its fate in 2025. The third candidate quietly disappeared around the same time.
Fierce Biotech described Pfizer's GLP-1 strategy as "hollowed out." The company had jettisoned its third and final oral GLP-1 agonist with nothing obvious to replace it.
Then came the Metsera acquisition, reportedly valued around $10 billion, which brought berobenatide into Pfizer's hands. That purchase is now the foundation of an ambitious plan: 10 Phase 3 trials for berobenatide in 2026 alone, spanning obesity, knee osteoarthritis, and obstructive sleep apnea. The first Phase 3 study (VESPER-6) is set to begin enrolling this month, with primary results expected by May 2028.
Wall Street's Verdict: Nice, But Is It Nice Enough?
Analyst reactions tell a nuanced story. The monthly dosing and tolerability profile got genuine enthusiasm. Citi called the successful weekly-to-monthly transition and the low discontinuation rates in VESPER-3 the "most compelling aspects" of the data.
But efficacy comparisons to the market leaders cooled some jets. Guggenheim described the results as "solid, but also relatively undifferentiated" from drugs already on the market or further ahead in development. Leerink's David Risinger was more pointed, calling the data "slightly inferior to LLY's Zepbound" on both efficacy and discontinuation rates.
Pfizer's stock dropped about 3% on the initial VESPER-3 readout. The concern: when you spend $10 billion on a drug, "solid" might not be enough.
The Competitive Chess Match
Berobenatide enters a battlefield that's gotten crowded fast. Weekly injectables from Novo Nordisk (semaglutide/Wegovy) and Eli Lilly (tirzepatide/Zepbound) dominate the market, with combined GLP-1 revenues exceeding $50 billion annually. Lilly's oral pill, orforglipron (now branded Foundayo), won FDA approval in April 2026, proving that daily pills can work too.
Next-gen agents like Lilly's retatrutide, a triple-hormone agonist, have posted weight loss numbers approaching 28% in trials. Novo's CagriSema combines semaglutide with an amylin analog for potentially superior results.
Berobenatide isn't going to win the weight-loss Olympics. Its edge is convenience. If you're a patient choosing between 52 weekly shots and 12 monthly ones (with comparable results), the math speaks for itself. Pfizer is betting that in a chronic disease requiring lifelong treatment, the drug patients actually keep taking beats the one they quit.
With Phase 3 kicking off now and over 20 obesity-related trials planned for 2026, Pfizer has gone all in on that bet. The next two years will tell us if monthly dosing is a game-changer or just a nice-to-have in a market that rewards maximum weight loss above all else.
Clinical & Regulatory
4 min read
Trodelvy Just Jumped the Line in Breast Cancer Treatment
The FDA just moved Gilead's Trodelvy from last-resort to first-choice in triple-negative breast cancer, the deadliest breast cancer subtype. It's a seismic shift for patients, a multi-billion-dollar opportunity for Gilead, and a surprisingly friendly outcome for Merck's Keytruda.
